Latest News and Press Releases

Parkinson's disease reversed for 200 human medical research patients

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

New York, July 11, 2023 (GLOBE NEWSWIRE) -- The global neurostimulation devices market is expected to grow at a CAGR of ~12% from 2023 to 2035. The market is estimated to garner a revenue of ~USD 34...

Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to...

Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 ...

Horsham, PA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease...

Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients...

LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...

BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...